118
Views
2
CrossRef citations to date
0
Altmetric
SHORT REPORT

Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study

ORCID Icon, , & ORCID Icon
Pages 1195-1203 | Received 23 Feb 2022, Accepted 08 Aug 2022, Published online: 31 Aug 2022

Figures & data

Table 1 Patient Characteristics at Enrollmenta

Figure 1 Distribution of CHRONICLE sites across the United States.

Figure 1 Distribution of CHRONICLE sites across the United States.

Figure 2 Overall rates of (A) asthma exacerbations, (B) exacerbation-related emergency department visits, and (C) asthma hospitalizations by month from July 2018 through July 2021. (A–C) Gray bands represent the implementation of state-level COVID-19 restrictions.

Figure 2 Overall rates of (A) asthma exacerbations, (B) exacerbation-related emergency department visits, and (C) asthma hospitalizations by month from July 2018 through July 2021. (A–C) Gray bands represent the implementation of state-level COVID-19 restrictions.

Figure 3 Monthly exacerbation rates by treatment category: 3-month moving averages. Gray bands represent the implementation of COVID-19 restrictions. Biologic use and SCS use were not mutually exclusive.

Abbreviations: 3 per. Mov. Avg., moving 3-month averages; SCS, systemic corticosteroids.
Figure 3 Monthly exacerbation rates by treatment category: 3-month moving averages. Gray bands represent the implementation of COVID-19 restrictions. Biologic use and SCS use were not mutually exclusive.

Figure 4 Proportion of patients receiving treatment with biologics from 2018 through 2020. The gray band represents the implementation of COVID-19 restrictions.

Abbreviation: Q, quarter.
Figure 4 Proportion of patients receiving treatment with biologics from 2018 through 2020. The gray band represents the implementation of COVID-19 restrictions.